Nuveen LLC Makes New $194,000 Investment in Ventyx Biosciences, Inc. $VTYX

Key Points

• Nuveen LLC has made a new investment in Ventyx Biosciences, Inc., purchasing 168,420 shares valued at approximately $194,000, representing a 0.24% ownership stake.
• Ventyx recently reported quarterly earnings of ($0.38) per share, which surpassed analysts' expectations of ($0.45).
• Following a rating adjustment, Wall Street has changed Ventyx Biosciences' rating from "sell" to "hold." The consensus target price for the stock is set at $7.50.

Nuveen LLC bought a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 168,420 shares of the company's stock, valued at approximately $194,000. Nuveen LLC owned 0.24% of Ventyx Biosciences as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new stake in Ventyx Biosciences during the first quarter worth approximately $28,000. Bank of America Corp DE boosted its position in Ventyx Biosciences by 376.4% during the fourth quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock worth $9,359,000 after purchasing an additional 3,376,446 shares during the period. BNP Paribas Financial Markets bought a new stake in Ventyx Biosciences during the fourth quarter worth approximately $276,000. Millennium Management LLC boosted its position in Ventyx Biosciences by 369.7% during the fourth quarter. Millennium Management LLC now owns 1,281,629 shares of the company's stock worth $2,807,000 after purchasing an additional 1,008,760 shares during the period. Finally, Two Sigma Investments LP boosted its position in Ventyx Biosciences by 79.8% during the fourth quarter. Two Sigma Investments LP now owns 476,291 shares of the company's stock worth $1,043,000 after purchasing an additional 211,421 shares during the period. Institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Trading Down 3.1%

VTYX opened at $2.52 on Friday. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $3.39. The stock has a market capitalization of $179.70 million, a price-to-earnings ratio of -1.50 and a beta of 0.95. The business has a 50 day moving average of $2.65 and a 200-day moving average of $1.93.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. Equities analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Ventyx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $7.50.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.